The identified KIR/HLA pair presented in this study may represent an effective predictive marker of HCC development after HBV infection, with additional use as a predictor of the efficacy of anti-HBV treatment with NUCs. The gene discussed is KIR3DL1; the disease is hepatocellular carcinoma.